Low grade inflammation with high blood sugar increases death risk
China: Serum hs-CRP can predict 10-year all-cause mortality in Chinese adults with hyperglycemia, according to a recent study in the journal Diabetes Research and Clinical Practice. This suggests that there is a need for giving more attention on the impact of low-grade inflammation on mortality in people with type 2 diabetes.
Studies in the past have established high sensitivity C-reactive protein (hsCRP), a biomarker of inflammation, as an independent predictor for CAD.
Guangwei Li, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, and colleagues examine whether high-sensitivity C-reactive protein (hs-CRP) can predict all-cause death in Chinese adults with hyperglycemia. A high level of CRP in the blood is a marker of inflammation.
The researchers recruited 237 diabetes and 49 prediabetes evolved from the participants with impaired glucose tolerance in the original Da Qing Diabetes Study. Blood hs-CRP level was measured at 2006. Ten-year death outcome was traced from 2006 to 2016. The association between hs-CRP level and the risk of all-cause death occurred over the subsequent 10 years was analyzed using the Cox model.
Key findings of the study include:
- During the follow-up, death occurred in 36 (37.9%) subjects in the highest hs-CRP tertile group (hs-CRP > 2.16 mg/L) and 19 (20.0%) in the lowest hs-CRP tertile group (hs-CRP < 0.82 mg/L).
- The corresponding incidence of all-cause death (per 1,000 person-years) was 44.7 and 21.6 in the two groups respectively.
- The highest hs-CRP tertile was associated with the increased risk of all-cause death significantly (hazard ratio 1.88) after controlling for traditional risk factors.
"Serum hs-CRP was predictive of 10-year all-cause death in Chinese adults with hyperglycemia, suggesting the impact of low-grade inflammation on mortality deserves more attention," concluded the authors.
The research titled, "Prediction of 10-year mortality using hs-CRP in Chinese people with hyperglycemia: Findings from the Da Qing diabetes prevention outcomes study," is published in the journal Diabetes Research and Clinical Practice.
DOI: https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(21)00021-8/fulltext
